ArriVent BioPharma (AVBP) Insider Peterson Buys 13,562 Shares

Kristine Peterson, an insider at AVBP, made a notable purchase of 13,562 shares on June 18, 2026. While the transaction price was not disclosed, shares of AVBP traded at approximately $31.74 on Tuesday.

Other Institutional Activity in AVBP

Suvretta Capital Management increased its stake in AVBP by 295,048 shares, bringing its total holdings to 4,401,083 shares valued at about $101.5 million. Infinitum Asset Management also added 25,000 shares, now holding 4,148,923 shares worth approximately $95.7 million. Meanwhile, HHLR Advisors and Orbimed Advisors maintained their positions without change, each holding 3,929,117 and 3,027,328 shares, respectively. FMR LLC reduced its holdings by 687,440 shares, resulting in a total of 3,016,132 shares valued at about $69.6 million.

ArriVent BioPharma, Inc. Stock Up 13.1%

AVBP shares traded near $31.74 on Tuesday. The stock has a varied institutional presence, with several key players adjusting their positions recently.

Insider Buying and Selling at ArriVent BioPharma, Inc.

On June 18, 2026, several insiders, including Kristine Peterson, Chris Nolet, John Hohneker, and Merdad Parsey, each acquired 13,562 shares of AVBP. Earlier in the year, on February 2, James Paul Kastenmayer, the General Counsel, and Winston Kung, the CFO, purchased 130,000 and 140,000 shares, respectively.

Analysts Set New Price Targets

On May 29, 2026, Truist Securities maintained its 'buy' rating on AVBP, setting a price target of $45. Citigroup also maintained its 'buy' rating with a target of $43 on May 13, 2026. Other firms like B. Riley Securities and Oppenheimer have similarly expressed positive outlooks, with price targets of $45 and $50, respectively.

Bottom Line

Kristine Peterson's recent share purchase highlights ongoing insider interest in AVBP. Institutional investors like Suvretta Capital and Infinitum Asset Management have also adjusted their holdings, reflecting varied strategies in response to market conditions. Analysts continue to maintain positive ratings, suggesting confidence in AVBP's potential, though these assessments are based on past data and may not reflect future performance.